Prof. Dr. Matthias Schwab

• Academy of Science and Literature Mainz, Germany. Commission for Medical Research (2014-present, chair since 2015)
• Baden-Wuerttemberg-International, Germany. Elected Committee for the joint partnership between BW and Kanagawa (Japan) “Technologies in an aging society”, Yokohama (2015)
• European Assocation of Clinical Pharmacology and Therapy (EACPT) Council of EACPT (2010-2019), Executive Committee (2010-2017), Delegate to the Council (2020 - present)
• European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) . EFLM-ESPT working group on Personalized Laboratory Medicine (WG-PLM) (2012-2023)
• European Health Foundation (EHF) . Board of Trustees (2013-2018)
• European Medicines Agency (EMEA) . CPMP Pediatric Expert Group (PEG): Extraordinary member (2001-2004)
• German Diabetes Association (DDG). Scientific Advisory Board “AG Molekularbiologie und Genetik des Diabetes mellitus“ (2017-present)
• German Federal Institute of Drugs and Medicinal Products (BfArM) . Expert Group "Drugs for Children and Adolescents" according to AMG (2004-present: Full Member, and Vice Chair), Member of the Scientific Advisory Board (01/2022-12/2025)
• German Medical Association (AkdÄ) . Drug Therapy Safety Commission. (Arzneimitteltherapie-sicherheit in Deutschland (AMTS)) (2007-2024)
• German Morbus Crohn/Colitis Ulcerosa Association DCCV e.V. Scientific Advisory Board (2014-2022)
• German Society of Child and Adolescent Medicine. Committee of Drug Safety (KASK) (1998-present)
• German Society of Clinical Pharmacology (DGKliPha) . Chair (2013-2018), Boardmember (2019-present)
• German Society of Experimental and Clinical Pharmacology and Toxicology (DGPT) . President (2015, 2018)
• "HEXAL-Iinitiative drugs for children" , Member of the Expert Group (2004-2010)
• Initiative Medicines for Children e.V. (IKAM) Member of the expert advisory board, (2012-present)
• Institute of Digital Medicine (IDM Foundation) Stuttgart. Executive Board (2011-2013), Board of trustees (2013-2017)
• Interfaculty Centre of Pharmacogenomics and Drug Research (ICEPHA) , Tübingen-Stuttgart. Scientific Board, Vice Chair, and Chair (2006-present)
• International Union of Basic and Clinical Pharmacology (IUPHAR) . Sub-Committee Pharmacogenetics (2008-2022), Sub-Committee Drug Metabolism and Transporter (2010-2014 Executive Board, 2014-2018 Vice Chair, 2019-2022 Chair); Sub-Committee Pharmacogenetics, Drug Metabolism and Transport (2023 – present, Member)
• NCT-Southwest, Managing Director / Spokesman of the location Stuttgart (2023-present)
• Reference Institute for Bioanalytics (Foundation for Pathobiochemistry and Molecular Diagnostics), Bonn, Member of the Scientific Board (2014-present)
• Robert Bosch Stiftung, Stuttgart, Germany. Selection Committee „Fast Track – Exzellenz und Führungskompetenz für Wissenschaftlerinnen auf der Überholspur“ (2011, 2015, 2017)
• University of Helsinki. International Evaluation Board of the Election of the Erkko Professorship (2014, 2017)
• Verbund Klinische Pharmakologie in Deutschland e.V. Chair of the 17th Annual Meeting 2016 and of the 18th Annual Meeting 2017
• Vienna Science and Technology Fund, Vienna, Austria. International Evaluation Board of Life Sciences Call 2016 Personalised Medicine (2015-2016)

Bosch Health Campus GmbH, Stuttgart, Germany

• Research Council (1999-2005), Chair (2007- present)
• Medical Council (2007-present)

Eberhard Karls University Tuebingen, Germany

• Committee for Research Strategy & Coordination, Rektorat University Tübingen (2012- 2019)
• Board of Members / Executive Board of the Comprehensive Cancer Center (CCC) University Hospital Tübingen (2009-present)
• Council of the Medical Faculty University Tübingen (2010-present)
• Extended Research Committee Med. Faculty University Tübingen (2008-2020)
• Natural and Medical Sciences Institute (NMI, non-profit public-law foundation) Reutlingen, Germany, First Deputy Chairman (2010-present)
• DFG Excellence Strategy by the German Federal and State Governments Cluster of Excellence. Image-Guided and Functionally Instructed Tumor Therapies (iFIT), Member of the Steering Committee (PI-Representative for Non-university Research Institutions) (2019-present)
• ZKS (Zentrum für Klinische Studien), Medical Faculty, University Tuebingen, Member of the Managing Board

Community Service / Ethical Committees

• Committee for qualification as medical specialist in clinical pharmacology, Regional Medical Chamber Nordwürttemberg (2013-present)
• Ethical Committee of the Medical Chamber of the State Baden-Württemberg (2004-present)
• Ethical Committee of the University Hospital Tübingen (2017 - present)

Public (regional, federal) appointments

• State Baden-Württemberg
  - Forum Gesundheitsstandort Baden-Württemberg (2018 – present)


• Medical Chamber of the State Baden-Württemberg
  - Authorization for advanced training in clinical pharmacology for a period of 48 months in accordance with WBO 2020, granted by the North
    Württemberg District Medical Association (together with OÄ Dr. Svitlana Igel; 2024 - present)
  - Member of the Commission for continuing education (Weiterbildungsausschuss), Regional Medical Chamber Südwürttemberg (2022 – 2027)
  - Widerspruchsausschuss postgraduate training (2015-present)
  - Committee for qualification as medical specialist in clinical pharmacology, Regional Medical Chamber Nordwürttemberg (2013-present)


• German Federal Institute of Drugs and Medicinal Products (BfArM)
  - Specialized Ethics Committee for Special Procedures at the BfArM according to § 41c Absatz 1 AMG (2025-2030)


• Federal German Ministry of Health, Berlin
  - Gendiagnostikkommission (2010-2013)
  - Committee of Experts on Drug Prescription (2013-present)
  - Expert committee for standard approvals (2017–2021)

• Baden-Württemberg State Chamber of Pharmacists
  - Approval as a training center for the field of drug information (2023–2028)

• Honorary Member of the Finnish Society of Clinical Pharmacology (2024)
• Member of the Academia Europaea (2022)
• Fellow of the British Pharmacological Society (2021)
• Adjunct Professor for "Clinical Pharmacology" and "Biochemistry" at Yerevan State Medical University, Armenia (2018-2028)
• Thomson Reuters/Clarivate Analytics Highly Cited Researchers, rubric “Pharmacology and Toxicology”/ "Cross Field" (2015/2016/2018/2021/2022/2023/2024)
• Robert-Pfleger Research Award (2016)
• Conferment of the “Staufer-Medal” by the Prime Minister of Baden Württemberg (2015)
• Celebratory Speech ("Vom Wert der Arznei - Wege zu einer zielgerichteten Therapie") at the Annual Meeting of the Academy of Science and Literature, Mainz, Germany (2014)
• Member of the German National Academy of Sciences ‘Leopoldina’ (2014)
• Most cited German pharmacologist in Europe (LabTimes, 2013)
• Member of Faculty of 1000 Prime, Section Pharmacogenomics (2012-2016)
• Full Member of the Academy of Science and Literature, Mainz, Germany (2012)
• Authorization of IKP (M. Schwab) as a training center for ‘Drug information’ by the Chamber of Pharmacists of the State Baden-Württemberg (2010, renewal 2023 - 2028)
• EACPT Key lecture “Personalized Medicine beyond Pharmacogenetics”, 16th World Congress on Basic and Clinical Pharmacology, Copenhagen, Denmark (2010)
• Most cited pharmacologist in German-speaking countries (Laborjournal, 2009)
• Galenus von Pergamon Award (2005)
• Friedrich Hartmut Dost Award (2004)
• Scholarship according to the "Bayerischen Begabtenförderungsgesetz" (1983-1990)

Editor in Chief

• Pharmacogenetics & Genomics
• Drug Research

Section Editor

• "Pharmacogenomics and Personalized Medicine" of Genome Medicine (2008-2024)
• Monatsschrift Kinderheilkunde, Section Editor „Drug Therapy” (2015-2019)
• Journal of Personalized Medicine, Editor of Special Issue "Personalized Medicine Based on Drug Transporter Genetic Heterogeneity" (2019)

Editorial Boards

• Genome Medicine (2024-present)
• British Journal of Clinical Pharmacology, Member of the International Editorial Board (2013-present)
• Clinical Chemistry (2008-2014)
• Therapeutic Drug Monitoring (2010-present)
• Journal of Personalized Medicine (2015-present)
• Biomedicine Hub (2017-2019)
• Clinical Pharmacology & Therapeutics (2020-present)

Book Editor

• Cascorbi I, Schwab M. Prescision Medicine. Handbook of Experimental Pharmacology, vol 280. Springer, Cham, 2023
• Kiess W., Schwab M., van den Anker J. (eds) Pediatric Pharmacotherapy. Handbook of Experimental Pharmacology, vol 261. Springer, Cham, 2020
• Schwab M, Kaschka WP, Spina E (eds.). Pharmacogenomics in Psychiatry. Advances in Biological Psychiatry. Vol. 25. Karger, 2010
• Seyberth WH, Rane A, Schwab M (eds.). Handbook of Experimental Pharmacology. Pediatric Clinical Pharmacology, 14th Edition, Springer, 2011

Selection

• BMBF Excellence Strategy by the German Federal and State Governments Cluster of Excellence. Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
• BMBF Virtual Liver Network
• BMBF HepatoSys Network
• BMBF LiSym Network
• DFG Excellence cluster EXC 2180  Individualisierung von Tumortherapien durch molekulare Bildgebung und funktionelle Identifizierung therapeutischer Zielstrukturen iFIT
• DFG Der Einsatz von Spatial Transcriptomics zum besseren Verständnis der Tumor-Heterogenität für die Prognose und die Therapieresistenz beim Nierenzellkarzinomspatial (Schwab – Schaeffeler)
• DFG Graduiertenkolleg: "Nicht-kanonische G-Protein-abhängige Signalwege: Mechanismen, Funktionen, Konsequenzen"
• DFG KFO 274 Thrombozyten - Molekulare Mechanismen und translationale Bedeutung, University of Tuebingen, Germany
• DFG German-African Cooperation Projects in Infectious diseases, University Hospital Tuebingen, Germany
• EU CONNECT4Children (IMI2 call 2017), European Paediatric Clinical Trials Network (c4c)
• EU Horizon 2020 IMI2, Connecting digital mobility assessment to clinical out-comes for regulatory and clinical endorsement (MOBILISE-D)
• GANI_MED (Greifswald Approach to Individualized Medicine), German Federal Ministry for Education and Research (BMBF)
• German Center for Infection and Research (Dt. Zentrum für Infektionsforschung, IZF)
• German Consortium for Translational Cancer Research (Dt. Konsortium für Translationale Krebsforschung, DKTK)
• International Clinical Pharmacogenetics Implementation Consortium (Member, USA)
• International Clopidogrel Consortium (Member of Steering Committee, Baltimore, USA)
• International PGx nomenclature working group (USA- Centers for Disease Control and Prevention)
• International TPMT nomenclature committee (http://www.imh.liu.se/tpmtalleles?l=en)
• Kinacept consortium: Novel anti-inflammatory compounds for autoimmune diseases (FP7-SME-1)
• NeuRoSIS-Consortium: Efficacy and Safety of Inhaled Budesonide in very Preterm Infants at risk for Bronchiopulmonary Dysplasia (FP5 Health 2009)
• PREDICT: Holistic Multi-Scale Modeling of Targeted Protein Therapeutics Action: Towards Predicting Effective Treatment of Cancer (BMBF)
• SFB 685 “Immunotherapy: Molecular Basis and Clinical Application”, University of Tuebingen, Germany
• The Pharmacogene Variation (PharmVar) Consortium, Kansas City, USA
• U-PGx consortium: Making actionable pharmacogenomics data and effective treatment optimization accessible to every European citizen“(EU, Horizon 2020)
• Verbundprojekt FORSYS-Kooperation „Ein systembiologischer Ansatz zur prädiktiven Krebstherapie“ (BMBF)
• Verbundprojekt INFORM „Individualized Therapy for Relapsed Malignancies in Childhood“, Deutsche Krebshilfe e.V. (Deutsche Kinderkrebsstiftung, DKTK)

national / international - including sections

• EU FP7-People-ITN: Marie Curie Initial Training Network “Fighting Drug´Failure”. Lead Applicant and Consortium heads: Schwab M & Brauch H
• EU CONECT4Children (IMI2 call 2017: European Paediatric Clinical Trials Network, M. Schwab, German Coordinator)
• U-PGx consortium: Making actionable pharmacogenomics data and effective treatment optimization accessible to every European citizen“(EU, Horizon 2020, M. Schwab, Vice Chair)
• BMBF (01ZP0502): Open label, prospective, observational, multi-centre trial in postmenopausal, hormonereceptor positive breast cancer patients treated with either tamoxifen or an aromatase inhibitor (IKP211). Study PI (since 2007)
• ICEPHA Minigraduate College Membrane associated drug targets in Oncology
• BMBF Verbundprojekt “Genotype and phenotype guided supplementation of TAMoxifen standard therapy with ENDOXifen in breast cancer patients (TAMENDOX)

• International Society of the Study of Xenobiotics (ISSX)
• American Society for Clinical Pharmacology and Therapeutics (ASCPT)
• European Association of Clinical Pharmacology and Therapeutics (EACPT)
• European Society for Developmental, Perinatal & Pediatric Pharmacology (ESDPPP)
• German Society of Clinical and Experimental Pharmacology (DGPT)
• German Society of Child and Adolescent Medicine (DGKJ)
• German Society of Nephrology (GPN)
• German Society for Clinical Chemistry and Laboratory Medicine e.V. (DGKL)
• Deutsche Morbus Crohn / Colitis Ulcerosa Vereinigung e.V. (DCCV)